314 related articles for article (PubMed ID: 28882698)
41. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
42. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
[TBL] [Abstract][Full Text] [Related]
43. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
44. MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition.
Machackova T; Mlcochova H; Stanik M; Dolezel J; Fedorko M; Pacik D; Poprach A; Svoboda M; Slaby O
Tumour Biol; 2016 Nov; 37(11):14653-14658. PubMed ID: 27619681
[TBL] [Abstract][Full Text] [Related]
45. Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Zhai L; Li S; Li H; Zheng Y; Lang R; Fan Y; Gu F; Guo X; Zhang X; Fu L
Int J Clin Exp Pathol; 2015; 8(6):7059-71. PubMed ID: 26261599
[TBL] [Abstract][Full Text] [Related]
46. Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome.
Katayama A; Handa T; Komatsu K; Togo M; Horiguchi J; Nishiyama M; Oyama T
Pathol Int; 2017 Aug; 67(8):404-413. PubMed ID: 28699235
[TBL] [Abstract][Full Text] [Related]
47. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
Yang F; Zhang W; Shen Y; Guan X
Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
[TBL] [Abstract][Full Text] [Related]
48. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer.
Yang L; Feng Y; Qi P; Xu S; Zhou Y
J Biol Regul Homeost Agents; 2016; 30(4):1041-1045. PubMed ID: 28078851
[TBL] [Abstract][Full Text] [Related]
50. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
51. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
52. MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer.
Zheng M; Wu Z; Wu A; Huang Z; He N; Xie X
Tumour Biol; 2016 Jul; 37(7):8599-607. PubMed ID: 26733177
[TBL] [Abstract][Full Text] [Related]
53. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.
Cheung SY; Boey YJ; Koh VC; Thike AA; Lim JC; Iqbal J; Tan PH
Breast Cancer Res Treat; 2015 Aug; 152(3):489-98. PubMed ID: 26123543
[TBL] [Abstract][Full Text] [Related]
54. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
55. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
[TBL] [Abstract][Full Text] [Related]
56. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
57. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
[TBL] [Abstract][Full Text] [Related]
58. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
59. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
60. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
